Drugs / TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06158828 Background | Nov 2024 → Sep 2028 expected | acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06158828 ↗ |
| Modality | Cell therapy | “The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0.” NCT06158828 ↗ |